(Health-NewsWire.Net, May 27, 2016 ) Publisher's, 'Essential Thrombocythemia - Pipeline Review, H1 2016', provides an overview of the Essential Thrombocythemia pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Essential Thrombocythemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Essential Thrombocythemia and features dormant and discontinued projects.
Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Other Key Points in Report:
- The report provides a snapshot of the global therapeutic landscape of Essential Thrombocythemia - The report reviews pipeline therapeutics for Essential Thrombocythemia by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Essential Thrombocythemia therapeutics and enlists all their major and minor projects - The report assesses Essential Thrombocythemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Essential Thrombocythemia
Ask for Sample Report @ http://www.reportsweb.com/inquiry&RW0001242076/sample
Table of Content: An Overview
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Essential Thrombocythemia Overview 7 Therapeutics Development 8 Pipeline Products for Essential Thrombocythemia - Overview 8 Essential Thrombocythemia - Therapeutics under Development by Companies 9 Essential Thrombocythemia - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Essential Thrombocythemia - Products under Development by Companies 13 Essential Thrombocythemia - Companies Involved in Therapeutics Development 14 ANP Technologies, Inc. 14 Aop Orphan Pharmaceuticals AG 15 F. Hoffmann-La Roche Ltd. 16 Galena Biopharma, Inc. 17 Gilead Sciences, Inc. 18 Incyte Corporation 19 Italfarmaco S.p.A. 20
Ask for Discount on Report @ http://www.reportsweb.com/inquiry&RW0001242076/discount
MEI Pharma, Inc. 21 Novartis AG 22 PharmaEssentia Corporation 23 Essential Thrombocythemia - Therapeutics Assessment 24 Assessment by Monotherapy Products 24 Assessment by Target 25 Assessment by Mechanism of Action 27 Assessment by Route of Administration 29 Assessment by Molecule Type 31 Drug Profiles 33 anagrelide hydrochloride CR - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 anagrelide hydrochloride PR - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Drug to Inhibit Ribonucleotide Reductase for Polycythemia Vera and Essential Thrombocythemia - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 givinostat - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 momelotinib dihydrochloride - Drug Profile 39
Purchase Complete Report @ http://www.reportsweb.com/buy&RW0001242076/buy/2000
About Us:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
Contact Us: Email: sales@reportsweb.com Call: +1-646-491-9876
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|